Sberbank, together with the AIRI Institute, is establishing a center for the development of artificial intelligence-based drugs in Russia. This was stated by Andrey Belevtsev, senior vice president and head of Sberbank’s Technological Development block, at the AI Journey conference. The new center, called AIDD, will search for drug molecules using advanced artificial intelligence technologies.
Belevtsev said that the main purpose of the center is to prolong active life and improve its quality. To achieve this, it is planned to accelerate the process of creating original drugs and reduce development costs. It will also create a research platform that will help apply AI in the search for biological targets and molecules, their validation and pre-clinical testing with pharmaceutical companies.
AIDD will focus on advances in the treatment of cancer, Alzheimer’s disease, diabetes and obesity. Belevtsev emphasized that this is only the beginning of large-scale studies that can take the Russian pharmaceutical industry to a new level.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
